While the NK cell exosome product became the first in the industry to obtain FDA DMF approval, Shenzhen Cell Valley simultaneously conducted comprehensive safety and efficacy uations for both injectable and topical formulations. Notably, in a drug-induced dermatitis model, the exosomes significantly outperformed saline and umbilical cord mesenchymal stem cell (MSC) exosomes in enhancing skin condition through continuous topical application. **Experimental Design Overview** **Animal Model**: Dermatitis induced by chemical drug stimulation using SD rats (n=3). **Treatment**: Continuous application of exosomes for 3 days. **Control Group**: Normal saline. **Treatment Group**: NK exosomes or MSC exosomes. **Observation Points**: Day 1 and Day 4 after application. **uation Criteria**: Skin integrity, inflammatory response, wound color changes, and epidermal repair. **Results Display** (Unpublished images provided by Shenzhen Cell Valley; reproduction prohibited without authorization) The following shows actual photographic results of the three groups on Day 1 and Day 4: 1. **Normal Saline Group (Control)** -Day 1: Clear wound area with limited epidermal protection-Day 4: Significant wound redness and inflammation with limited repair effect 2. **NK Exosome Group** -Day 1: Smooth skin surface with mild inflammation Day 4: Wound showed significant contraction with reduced redness and swelling, and the repaired area appeared clear and smooth. Overall performance: The NK exosome group demonstrated the fastest healing speed, best skin integrity, and least inflammatory response among the three groups (experimental results showed NK exosomes significantly promote skin barrier repair). 3. MSC exosome group: Day 1: Smooth skin with mild reaction. Day 4: Healing degree surpassed saline control but remained significantly weaker than NK exosome group. Summary: NK exosomes exhibit superior skin repair capabilities. In this 3-day continuous topical application experiment, NK exosomes demonstrated the best wound closure and inflammatory control effects, showing marked superiority over MSC exosomes and far better than the saline control group. These data further confirm that NK exosomes, as next-generation bioactive delivery carriers, hold broad application prospects in topical formulations for skin repair, anti-inflammatory, and anti-aging purposes. Extended reading: NK exosomes are naturally rich in: cytotoxic granules (granzyme, perforin trace signals), anti-inflammatory factors, extracellular matrix regulatory molecules, and miRNA combinations that promote tissue healing. These components play a significant role at the repair site by inhibiting local inflammation, enhancing skin barrier integrity, accelerating keratinocyte migration, and facilitating a more standardized re-epithelialization process. NK exosomes are not only "safe" but also "highly active," serving as a natural regulatory system for skin regeneration. This animal study demonstrates that NK exosomes are not only applicable to injectable drugs but also exhibit topical efficacy, significantly expanding their commercial potential. For the first time, it validates the dermatological effects of topical NK exosomes, providing foundational evidence for future development of premium skincare products, medical-grade repair formulations, postoperative healing dressings, and topical biologics. NK exosomes thus emerge as one of the few triple-value platforms combining pharmaceutical, medical device, and skincare applications. Shenzhen Cell Valley will strategically position pharmaceutical-grade NK exosomes across three key sectors: 1) Healthcare: For skin injuries, radiation-induced dermatitis, diabetic wounds, and postoperative recovery. 2) Aesthetic Medicine: For anti-inflammatory relief, barrier repair, anti-aging, and precision skincare. 3) Consumer Market: As a premium active exosome skincare brand. The dual certification of experimental data and FDA DMF filing establishes a "science + regulation" framework. This groundbreaking achievement not only advances research but also secures regulatory approval: NK exosomes have obtained FDA DMF registration (DMF 043001) and now feature in vivo efficacy data supporting topical application. This makes it the world's first FDA-approved NK exosome product with verified skin repair efficacy. We invite global partners to utilize Cell Valley's GMP-grade NK exosomes for: Directly citing DMF for U.S. clinical trials; Serving as a foundation for exosome-based dermatological drug development; Acting as a core functional ingredient in aesthetic/repair products. Regulatory and industrial significance: As the first NK exosome material recognized by a regulatory authority (FDA) with in vivo efficacy validation, it sets a replicable industry template for exosomes functioning as "new drug carriers + skin repair components".